|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of high-intensity statins, ezetimibe, and if needed PCSK9 inhibitors merits consideration in such patients with ACS to optimize outcomes.
|
31250329 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to compare the effects of high-dose atorvastatin and rosuvastatin on serum oxidized low-density lipoprotein (oxidized-LDL) and PCSK9 levels in statin-naive patients with ACS.
|
30741744 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Addition of the PCSK9-inhibitor evolocumab to statin therapy might produce incremental growth in fibrous-cap thickness and regression of the lipid-rich plaque, which were associated with greater reduction of LDL-C even for a short term in the early phase of ACS.
|
31495548 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circulating PCSK9 concentrations discriminate patients with greater coronary atherosclerotic lesion extension and calcification, and are increased in patients with current ACS.
|
31493378 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this first randomized trial assessing a PCSK9 antibody in the very high-risk setting of ACS, evolocumab added to high-intensity statin therapy was well tolerated and resulted in substantial reduction in LDL-C levels, rendering >95% of patients within currently recommended target levels.
|
31479722 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, with no recognized lower-limit-associated intolerance or safety issues, even more intensive lowering of atherogenic cholesterol levels is supported by the following evidence base: (1) analysis of eight high-intensity statin-based prospective secondary prevention IVUS atheroma volume regression trials; (2) a distribution analysis of on-treatment, ezetimibe and background-statin, of the very low LDL-C levels reached and CVD event risk in the IMPROVE-IT ACS population; (3) the secondary prevention Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV) on background-statin; and (4) the secondary prevention population of Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER).
|
31754844 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy.
|
31121022 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some data suggest that circulating PCSK9 increases coronary plaque vulnerability, inflammation as well as platelet aggregation in the acute phase of ACS, potentially justifying earlier PSCK9 mAb treatment initiation.
|
30015301 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evolocumab, a proprotein convertase subtilisin/kexin type (PCSK9)-inhibitor resulting in rapid, marked LDL-C reduction, has been studied in hypercholesterolemic subjects without CVD and stabilized patients with CVD; the feasibility, safety, and efficacy of this treatment initiated in the acute phase of ACS remain unknown.
|
30421481 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Larger clinical studies are needed to evaluate whether PCSK9 serum levels could be used towards predicting the risk of ACS in patients with advanced carotid atherosclerosis.
|
29754909 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that increased PCSK9 levels are associated with higher platelet reactivity and are a possible predictor of ischemic events in ACS patients undergoing PCI.
|
27810295 |
2017 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study aims to (1) evaluate the status of lipid management and the subsequent risk of major cardiovascular events following hospitalisation of Japanese patients with ACS in real-world clinical practice; (2) determine the proportion of Japanese patients with ACS who achieve the lipid management goal and have a reduction of event risks with strict lipid management (low-density lipoprotein-cholesterol <1.81 mmol/L); (3) determine the prevalence of FH and (4) investigate the clinical significance of proprotein convertase subtilisin kexin 9 (PCSK9) level.
|
28674132 |
2017 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum PCSK9 concentrations were measured on admission (Day 0) for ACS by Elisa, and on every day of hospitalization.
|
28865748 |
2017 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the present statin therapy, and refer to ezetimibe and PCSK9 as novel or additional non-statin strategies in the management of ACS.
|
28325524 |
2017 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
A similar relationship was observed after application of 3-month intensive lipid-lowering therapy in patients with ACS (n = 30, PCSK9 [ng/mL] 281.1 ± 59.5 vs. 358.5 ± 74.7, p < 0.001, LDLR transcript [reaction units] 0.6 ± 0.32 vs. 1.87 ± 0.24, p < 0.001, number of LDLRs on monocytes [reaction units] 5.9 ± 3.1 vs. 22.3 ± 3.8, p < 0.001).
|
27665855 |
2016 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main objective of these studies is to evaluate the effect of PCSK9 inhibition on the occurrence of CVD events in patients with ACS.
|
25856746 |
2015 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whether PCSK9 mAbs decrease the rates of recurrent cardiovascular events within 3 months following ACS is questionable; however, these agents, unlike statins, may not have pleiotropic benefits on the unstable plaque.
|
23932550 |
2013 |